Trial · NCT03072147
Teriparatide as a Chondroregenerative Therapy in OA
NCT03072147, Phase 2, Completed, Christopher Ritchlin
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Teriparatide as a Chondroregenerative Therapy in OA. Trials, record NCT03072147. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03072147
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Teriparatide as a Chondroregenerative Therapy in OA
- NCT number
- NCT03072147
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 76 participants, actual
- Lead sponsor
- Christopher Ritchlin
- Conditions
- Knee Osteoarthritis, Cartilage Degeneration
- Interventions
- Teriparatide, Placebo
- First posted
- 2017-03-07
- Last updated
- 2023-05-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Knee MRI | Change from Baseline through study completion (baseline, 24 weeks, 48 weeks), an average of one year. | Analysis using Regional Cartilage Volume Segmentation |
| Secondary | Flexed Knee Radiograph | Change from Baseline through study completion (baseline, 24 weeks, 48 weeks), an average of one year. | Interpreted using fractal signature analysis. |
| Secondary | Urine Biomarker Analysis | Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year. | Analyzed immediately via enzyme-linked immunosorbent assay (ELISA) to quantify the following biomarker: urinary type II collagen |
| Secondary | Serum Biomarker Analysis | Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year. | Analyzed immediately via enzyme-linked immunosorbent assay (ELISA) to quantify the following biomarker: serum type II collagen degradation neoepitope. |
| Secondary | GAITRite | Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year. | Change in gait pre- and post-treatment analyzed using the GAITRite walking test. |
| Secondary | Timed up and go | Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year. | Change in gait pre- and post-treatment analyzed using the timed-up-and-go (TUG) test. |
| Secondary | WOMAC 3.1 | Change from Baseline through study completion (baseline, 12 weeks, 24 weeks, 48 weeks), an average of one year. | The Western Ontario and McMaster Universities Arthritis Index (WOMAC 3.1) measures pre- and post-treatment changes in subjective pain and functionality. |
| Secondary | PROMIS Depression | Change from Baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year. | The Depression scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures measures subjective changes in mood, pre- and post-treatment. |
| Secondary | PROMIS Pain Interference | Change from Baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year. | The Pain Interference scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures subjective changes in pain distress, pre- and post-treatment. |
| Secondary | PROMIS Physical Function | Change from Baseline through study completion (baseline, 4 weeks, 12 weeks, 24 weeks, 48 weeks), an average of one year. | Physical function scale from the Patient-Reported Outcomes Measurement Information System (PROMIS) measures subjective changes in mobility and activities of daily living, pre- and post-treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03072147
GET https://conductscience.org/api/trials/v1/NCT03072147/registered